PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
Aptocrom, whose core operations span pharmaceutical distribution and insulation materials, has posted operating losses in most recent quarters even as a large one-off gain in Q2 2026 coincided with a capital reduction, a third-party share placement, and a newly declared pivot toward virtual-asset business.
Q2 2026 revenue reached KRW 3.40 billion with a small operating profit of KRW 81 million, while owners' net income included a large one-off gain of KRW 46.08 billion.
Full-year 2025 revenue fell sharply to KRW 9.81 billion from KRW 16.40 billion a year earlier, with an operating loss of KRW 2.29 billion and an owners' net loss of KRW 5.56 billion.
Controlling shareholder Aprogen holds a 53.42% stake, rising to 80.49% including related parties, reflecting very high group control.
The board resolved a 20-to-1 reverse capital reduction in February 2026, which was approved at the March annual shareholders meeting, with trading resuming on June 1.
The company changed its name from AP Healthcare to Aptocrom and added blockchain and virtual-asset business purposes to its articles of incorporation.
Aptocrom is a small-cap KOSDAQ-listed distributor operating two core businesses: pharmaceutical distribution and insulation materials. As of Q2 2026, pharmaceutical business accounted for 70.7% of revenue and insulation business for 23.9%, meaning drug distribution makes up the bulk of sales.
The company, classified as a specialty wholesale distributor, listed on KOSDAQ in 2009 under its former name, AP Healthcare. Its controlling shareholder, Aprogen, holds a 53.42% stake, rising to 80.49% including related parties, reflecting a tightly controlled group affiliate structure.
The company recently amended its articles of incorporation to add blockchain and virtual-asset business and virtual-asset investment as new business purposes, changing its name to Aptocrom in the process.
This move aligns with a broader push across Aprogen Group affiliates (including Apthon and Entotech) into virtual-asset and bitcoin-treasury-style businesses, with combined cash holdings across the three listed affiliates reportedly exceeding KRW 100 billion as of the end of Q2 2026.
The legacy pharmaceutical and insulation businesses appear to operate on a small revenue base within a competitive domestic wholesale distribution landscape alongside numerous small and mid-sized peers.
In April 2026, the company decided on a third-party share placement to affiliate Nexconix to fund the acquisition of securities in another company.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩1.5B | -₩1.6B | −103.8% |
| 2025Q3 | ₩2.5B | -₩400M | −16.2% |
| 2025Q4 | ₩2.4B | -₩500M | −20.9% |
| 2026Q1 | ₩2.4B | -₩500M | −22.4% |
| 2026Q2 | ₩3.4B | ₩80,582,303 | 2.4% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩9.6B | -₩900M | -₩5.6B | −9.7% | −2.8% | 7.0% |
| 2023 | ₩16B | ₩200M | ₩4.3B | 1.2% | 1.5% | 10.2% |
| 2024 | ₩16.4B | ₩1B | -₩28.1B | 5.9% | −9.3% | 10.9% |
| 2025 | ₩9.8B | -₩2.3B | -₩5.6B | −23.3% | −1.8% | 4.5% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23
Annual revenue expanded from KRW 9.60 billion in 2022 to KRW 16.01 billion in 2023 and KRW 16.40 billion in 2024, before contracting again to KRW 9.81 billion in 2025.
Operating profit showed an improving trend from -KRW 0.93 billion in 2022 to KRW 0.19 billion in 2023 and KRW 0.97 billion in 2024, before swinging back to a KRW 2.29 billion loss in 2025.
Owners' net income has been highly volatile: a KRW 4.30 billion profit in 2023 was followed by a large KRW 28.09 billion loss in 2024, and a further KRW 5.56 billion loss in 2025.
On a quarterly basis, operating losses persisted from Q2 2025 through Q1 2026 at -KRW 1.57 billion, -KRW 0.41 billion, -KRW 0.51 billion, and -KRW 0.54 billion respectively, while owners' net losses continued from Q3 2025 through Q1 2026 at -KRW 1.16 billion, -KRW 3.34 billion, and -KRW 3.12 billion.
Revenue then rose to KRW 3.40 billion in Q2 2026, and operating profit turned positive at KRW 81 million for the first time in several quarters.
However, owners' net income for the same quarter reached KRW 46.08 billion, a figure far exceeding the scale of operating profit, which appears attributable to a non-operating one-off item and should not be read as reflecting sustained core profitability.
As a result of this one-off gain, cumulative owners' net income over the trailing four quarters (Q3 2025 through Q2 2026) reached KRW 38.45 billion, underscoring extreme quarter-to-quarter earnings volatility.
Meanwhile, operating cash flow remained positive across all periods regardless of net income swings, at KRW 17.28 billion in 2022, KRW 1.66 billion in 2023, KRW 4.71 billion in 2024, and KRW 2.44 billion in 2025.
The domestic pharmaceutical distribution industry is a mature market with numerous small and mid-sized wholesalers competing on thin margins, where bargaining power tends to correlate with scale.
The insulation materials business similarly operates as a small-scale materials distribution segment linked to construction and equipment cycles. Both segments position Aptocrom as a relatively small player given its 2025 revenue base of KRW 9.8 billion.
Separately, the Aprogen Group to which Aptocrom belongs has been expanding virtual-asset and blockchain-related new businesses across its affiliates, with Apthon (formerly Apt Neuroscience) pioneering a bitcoin-treasury-style business, followed by Entotech and Aptocrom sequentially adding similar business purposes.
Globally, companies such as Strategy and Metaplanet, which have adopted bitcoin as a treasury asset, are often cited as precedents for this model, but in Korea financial regulators do not recognize virtual assets as underlying assets for derivatives and apply strict standards to corporate account usage, meaning the institutional framework is still in formation.
As a result, observers note that domestic listed companies pursuing a crypto-treasury model face relatively greater regulatory and institutional uncertainty compared with overseas precedents.
Taken together, Aptocrom sits at a transitional juncture between a mature, low-growth traditional distribution business and a nascent virtual-asset venture for which the domestic institutional groundwork remains incomplete.
Following its April 2026 decision on a third-party share placement to affiliate Nexconix aimed at funding the acquisition of securities in another company, the specific target of that investment will be a key variable shaping the company's future business direction.
Having added blockchain and virtual-asset business purposes to its articles of incorporation, whether and when the company actually begins purchasing bitcoin or launching related operations is the next point to watch.
The 20-to-1 reverse capital reduction, resolved in February 2026 and completed with trading resuming in June, was aimed at improving the capital structure by offsetting accumulated deficits; while this appears to have eased capital-impairment concerns, whether core business profitability recovers remains to be seen.
The return to operating profit in Q2 2026 is a positive development, but it represents a single small profitable quarter, and whether this marks a sustained trend requires confirmation from subsequent quarterly results.
The specific driver behind the large one-off gain and whether similar items could recur are matters that warrant further review through footnote disclosures in upcoming semiannual and quarterly reports.
Amid the group-wide push into virtual-asset business, a clear roadmap on how Aptocrom will allocate resources between its legacy businesses (pharmaceuticals and insulation) and the new virtual-asset venture has not yet been disclosed.
The current share price trades at a level well below net asset value per share, a relationship worth noting.
However, this partly reflects the fact that a large one-off gain booked in Q2 2026 significantly inflated trailing four-quarter earnings, meaning multiples calculated on that earnings base differ in character from figures reflecting ordinary operating performance.
The company has not paid dividends in recent years, so there is no separate dividend-related reference point to consider.
Given the historically large swings between profit and loss across fiscal years, valuation metrics for this stock can also fluctuate sharply depending on the timing of one-off items, which is worth keeping in mind.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23
Q2 2026 revenue rose to KRW 3.40 billion from the prior quarter, and operating profit turned positive at KRW 81 million for the first time in several quarters. The same quarter's large owners' net income also expanded the equity base.
However, as this represents a single small profitable quarter, whether the trend continues requires further confirmation.
The debt ratio stood at just 4.5% at the end of 2025, reflecting very low financial leverage. Owners' equity has steadily expanded from KRW 19.89 billion in 2022 to KRW 30.66 billion... wait KRW 306.6 billion in 2025. The capital reduction also helped restructure the balance sheet by offsetting accumulated deficits.
As controlling shareholder Aprogen Group expands virtual-asset and blockchain businesses across its affiliates, Aptocrom has joined the effort through an articles amendment and name change.
Combined cash holdings across the three affiliates (Apthon, Entotech, Aptocrom) are reported to exceed KRW 100 billion, indicating available funding capacity for new ventures, though concrete business plans and execution timing remain uncertain.
2025 revenue fell sharply to KRW 9.81 billion from KRW 16.40 billion the prior year. Operating losses were recorded for four consecutive quarters from Q2 2025 through Q1 2026, and the full-year 2025 operating loss reached KRW 2.29 billion.
A clear recovery in profitability for the core pharmaceutical and insulation businesses has not yet been confirmed.
Q2 2026 owners' net income of KRW 46.08 billion vastly exceeds the same quarter's operating profit of KRW 81 million, suggesting it stems from a non-operating one-off factor. A precedent exists from 2024, when a large owners' net loss of KRW 28.09 billion was likewise driven by sizable non-operating items. Such volatility makes forecasting future earnings trends difficult.
The virtual-asset business remains at the articles-amendment stage, with no concrete business model or purchase plan yet disclosed.
In Korea, financial regulators do not recognize virtual assets as derivative underlying assets and apply strict standards to corporate account usage, leaving the institutional framework underdeveloped. In this environment, translating the new venture into tangible results could take time.
Controlling shareholder Aprogen, including related parties, holds an 80.49% stake, reflecting very high concentration of control. The April 2026 third-party placement was also directed to affiliate Nexconix, suggesting further intercompany capital or equity transactions could continue.
Minority shareholders may need to continue monitoring the terms and purposes of such related-party transactions.
The addition of virtual-asset and blockchain business purposes remains at an early stage, with no concrete plan yet confirmed. Korean financial regulators maintain a cautious stance on crypto-related derivatives and lending activity, leaving institutional uncertainty in place.
The lack of clarity on resource-allocation priorities between the legacy business and the new venture also warrants monitoring.
The stock experienced a trading suspension in early 2026 tied to the capital-reduction share re-listing process, resuming on June 1. Given its small market capitalization and limited free float, price volatility can be pronounced.
The possibility of further trading suspensions or re-listing procedures tied to future capital events (share issuances, reductions) cannot be ruled out.
The Q3 2026 quarterly report filing should clarify the nature and recurrence potential of the large one-off gain booked in Q2, as well as whether the return to operating profit is sustained.
Disclosures should be checked to confirm what specific securities acquisition the proceeds from the April third-party placement were ultimately used for.
It should be monitored, alongside developments at affiliates like Apthon, whether the newly added blockchain and virtual-asset business purposes progress to concrete execution such as actual bitcoin purchases or service launches.
Progress in Korean regulatory discussions on corporate virtual-asset accounts and derivatives could affect the pace of the group's new business rollout, warranting attention to related policy developments.
Aptocrom is a small distributor centered on pharmaceutical distribution and insulation materials that experienced revenue contraction and consecutive operating losses through 2025 before returning to a modest operating profit in Q2 2026.
However, the KRW 46.08 billion owners' net income booked in the same quarter is far out of proportion to operating profit and appears attributable to a one-off factor, meaning recent headline earnings may not fully reflect sustained core profitability.
On the balance sheet side, a low debt ratio and steadily growing equity base point to reasonable financial stability.
At the same time, the push into virtual-asset and blockchain business led by controlling shareholder Aprogen Group has advanced as far as a name change and articles amendment, but concrete business plans remain undisclosed and the initiative is still at an early stage.
A series of capital restructuring steps—including the 20-to-1 reverse capital reduction and third-party share placement—have been completed and trading has normalized, but subsequent quarterly results will need to be monitored to confirm genuine progress in both core-business recovery and new-business execution.
For observers, it will be important to track core-business profitability trends excluding one-off items alongside the concrete implementation timeline of the new venture.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.